Diabetes Increases Risk of Gastric Cancer After Helicobacter pylori Eradication: A Territory-Wide Study With Propensity Score Analysis

Abstract

Background: Whether diabetes mellitus (DM) increases gastric cancer (GC) risk remains controversial due to inadequate adjustment for important risk factors, including Helicobacter pylori (HP) status, concomitant medication usage and cancer site. We aimed to investigate whether type II diabetes mellitus (DM) increased GC risk in patients after HP treatment. Research design and methods: This was a territory-wide cohort study of patients aged ≥45 years who had received clarithromycin-based triple therapy for HP between 2003 and 2012 in Hong Kong. Data were retrieved from the public electronic health database. Observation started from HP therapy to GC diagnosis, death or end of study (December 2015). Exclusion criteria included type I DM, GC diagnosed within first year of HP therapy, prior GC or gastrectomy, and retreatment for HP. The adjusted hazard ratio (aHR) of GC with type II DM was calculated by Cox model with propensity score regression adjustment for 20 covariates (age, sex, comorbidities and medications). Results: During a median follow-up of 7.1 years (IQR:4.8-9.3), 153 (0.33%) of 46,460 patients developed GC at a median age of 72.4 years. Type II DM was associated with an increased GC risk (aHR:1.73; 95% CI:1.08-2.79). Stratified analysis showed increase in risk for cardia cancer only (aHR:3.40, 95% CI:1.45-7.97) and those with suboptimal DM control (time-weighted average HbA1c ≥6.0% [42mmol/mol]; aHR:1.68, 95% CI:1.07-2.63). Conclusions: Type II DM was associated with an increased GC risk among HPeradicated patients, in particular cardia GC and those with suboptimal DM control.

Nonsteroidal anti‐inflammatory drugs but not aspirin are associated with a lower risk of post‐colonoscopy colorectal cancer

“…The CDARS records all patient's demographics and clinical data including hospitalisation, visits to outpatient clinics, investigation procedures and results, endoscopic and surgical procedures, as well as drug prescription and dispensing history. A number of territory‐wide studies have been conducted using the CDARS, with a high degree of coding accuracy (>90%) of the International Classification of Diseases, Ninth Revision (ICD‐9) codings …”

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect

“…Furthermore, miRNA-130a may increase the radiosensitivity of rectal cancer cells by directly targeting SOX4 [ 62 ]; since T2DM has been associated with a 1.3-fold increased risk of colorectal cancer, further research in this field is warranted too [ 63 ]. Additionally, microRNA-130a, cooperatively with microRNA-145, through the inactivation of Runt-related transcription factor 3, increases cell proliferation and tumour angiogenesis in gastric cancer [ 64 ]; since T2DM increases the risk of gastric cancer following Helicobacter pylori eradication [ 65 ], this represents another field that deserves further investigation.…”

Calcium channel blockers are associated with lower gastric cancer risk: A territory‐wide study with propensity score analysis

“…Potential risk factors for GC included the age of receiving triple therapy, sex, smoking, alcohol use, past history of peptic ulcer disease and other comorbidities (diabetes mellitus [DM], 33 hypertension, dyslipidemia, obesity, congestive heart failure, atrial fibrillation, ischemic heart disease, chronic renal failure, cirrhosis, stroke), as well as the use of other medications (aspirin, NSAIDs, 17 metformin, 19 statin 18 and PPIs 16 ). Smoking‐related diagnoses were identified by an ICD‐9 code of V15.82 or indirectly by the presence of chronic obstructive pulmonary disease.…”